查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591796

血友病治療市場：依產品類型、適應症、分佈 - 全球預測 2025-2030

Hemophilia Treatment Market by Product Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates), Disease Indication (Hemophilia A, Hemophilia B, Polyethylene), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年血友病治療市值為143.2億美元，預計到2024年將達到152.3億美元，複合年成長率為6.45%，預計到2030年將達到221.8億美元。

血友病治療包括多種治療藥物，包括因子替代療法、基因療法和非因子療法，旨在控制以凝血蛋白缺乏為特徵的出血性疾病。對血友病晚期治療的需求源於透過減少出血事件、提高身體獨立性和盡量減少關節損傷來提高患者生活品質的需要。這些治療可用作預防性治療和按需治療，其中預防性治療用於防止嚴重血友病患者的自發性出血。主要最終使用者包括醫院、專科診所和家庭護理機構，反映了多樣化的護理管理需求。該市場受到血友病管理意識的提高、政府積極主動的舉措、藥物進步以及血友病遺傳患病率增加等因素的支持。隨著基因療法的興起（有望提供潛在的治療方法）以及長效重組和非因子療法的發展，存在著巨大的商機。由於醫療需求未被滿足，醫療保健普及率不斷提高的新興市場提供了更大的成長機會。然而，治療成本上升、嚴格的法律規範以及開發抑制劑的風險等挑戰構成了重大障礙。此外，新興市場有限的醫療基礎設施可能會阻礙市場擴張。生物技術、個人化醫療和具有成本效益的製造方法的創新可以推動業務成長。在這些領域的投資以及技術開發和市場滲透的策略夥伴關係都是可取的。市場的特點是競爭激烈、研究不斷、產品發布頻繁。公司應該專注於讓治療更安全、更有效、更容易獲得。隨著市場多元化和快速發展，維持強力的上市後監測以降低風險並持續調整病患教育對於確保長期成功至關重要。

主要市場統計
基準年[2023] 143.2億美元
預測年份 [2024] 152.3億美元
預測年份 [2030] 221.8億美元
複合年成長率（%） 6.45%

市場動態：快速發展的血友病治療市場的關鍵市場洞察

血友病治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 血友病患者數量增加
    • 提高對血友病的診斷和認知
    • 對重組凝血因子 VIII 和血漿凝血因子 IX 的需求不斷增加
  • 市場限制因素
    • 與血漿衍生產品相關的嚴重副作用
  • 市場機會
    • 提高診斷率及預防性治療
    • 血友病治療新進展與創新
  • 市場挑戰
    • 重組產品高成本且政府法規嚴格

波特五力：開拓血友病治療市場的策略工具

波特的五力架構是了解血友病治療市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解血友病治療市場的外在影響

外部宏觀環境因素在塑造血友病治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解血友病治療市場的競爭格局

血友病治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣血友病治療市場供應商的績效評估

FPNV定位矩陣是評估血友病治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製血友病治療市場的成功之路

血友病治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 血友病患者增加
      • 提高對血友病的診斷和認知
      • 對重組和血漿衍生的因子 VIII 和因子 IX 的需求增加
    • 抑制因素
      • 與血漿衍生產品相關的嚴重副作用
    • 機會
      • 提高診斷率並增加預防性治療的使用
      • 血友病治療新進展與創新
    • 任務
      • 重組產品的高成本和嚴格的政府法規
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 血友病治療市場：依產品類型

  • 抗纖溶藥
  • 去氨加壓素
  • 血漿衍生凝血因子濃縮物
  • 重組凝血因子濃縮物

第7章 血友病治療市場：依疾病適應症

  • A型血友病
  • B型血友病
  • 聚乙烯

第8章 血友病治療市場經銷商

  • 電子商務
  • 醫院藥房
  • 零售藥房

第9章美洲血友病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區血友病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的血友病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Aptevo Therapeutics
  • Biogen Inc.
  • Biotest AG
  • Bioverativ Inc.
  • CSL Behring
  • F. Hoffmann-La Roche AG
  • Ferring BV
  • Genentech, Inc.
  • Grifols SA
  • Kedrion SPA
  • LAKEMEDEL AB
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4316E4E894CE

The Hemophilia Treatment Market was valued at USD 14.32 billion in 2023, expected to reach USD 15.23 billion in 2024, and is projected to grow at a CAGR of 6.45%, to USD 22.18 billion by 2030.

Hemophilia treatment encompasses a wide array of therapeutics, including factor replacement therapies, gene therapy, and non-factor therapies aimed at managing bleeding disorders characterized by a deficiency in blood-clotting proteins. The necessity for advanced hemophilia therapies stems from the need to elevate patients' quality of life by reducing bleeding episodes, improving physical independence, and minimizing joint damage. These treatments find applications in both prophylactic and on-demand settings, with prophylaxis being favored to prevent spontaneous bleeding in severe hemophilia cases. Key end-users include hospitals, specialty clinics, and home-care settings, reflecting the diverse treatment administration requirements. The market is propelled by factors such as heightened awareness about hemophilia management, favorable government initiatives, advancements in pharmaceutical products, and the growing genetic prevalence of the disorder. Prominent opportunities lie in the rise of gene therapy, which promises a potential cure and the development of long-acting recombinant and non-factor therapies. Emerging markets with increasing healthcare access offer substantial growth opportunities due to unmet medical needs. However, challenges like the high cost of therapies, stringent regulatory frameworks, and the risk of inhibitor development pose significant hindrances. Additionally, limited healthcare infrastructure in developing regions can impede market expansion. Innovation in bioengineering, personalized medicine, and cost-efficient manufacturing methods can fuel business growth. Investment in these areas, along with strategic partnerships for technology development and market penetration, is advisable. The hemophilia treatment market is characterized by intense competition with ongoing research and frequent product launches. Firms should focus on enhancing therapy safety and efficacy, and increasing accessibility. Maintaining robust post-market surveillance to mitigate risks and continuously tailoring patient education will be critical in ensuring long-term success as the market diversifies and evolves rapidly.

KEY MARKET STATISTICS
Base Year [2023] USD 14.32 billion
Estimated Year [2024] USD 15.23 billion
Forecast Year [2030] USD 22.18 billion
CAGR (%) 6.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemophilia Treatment Market

The Hemophilia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing number of cases of hemophilia
    • Rising diagnostic and awareness related to Hemophilia
    • Increasing demand for recombinant and plasma-derived factor VIII and factor IX
  • Market Restraints
    • Serious adverse effects associated with plasma-derived products
  • Market Opportunities
    • Increased diagnosis rate and rise in the use of prophylactic treatment
    • Emerging advances and innovations in hemophilia treatment
  • Market Challenges
    • High cost of recombinant products and stringent government regulations

Porter's Five Forces: A Strategic Tool for Navigating the Hemophilia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemophilia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemophilia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemophilia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemophilia Treatment Market

A detailed market share analysis in the Hemophilia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemophilia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemophilia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemophilia Treatment Market

A strategic analysis of the Hemophilia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemophilia Treatment Market, highlighting leading vendors and their innovative profiles. These include Aptevo Therapeutics, Biogen Inc., Biotest AG, Bioverativ Inc., CSL Behring, F. Hoffmann-La Roche AG, Ferring B.V., Genentech, Inc., Grifols SA, Kedrion S.P.A, LAKEMEDEL AB, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Hemophilia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates.
  • Based on Disease Indication, market is studied across Hemophilia A, Hemophilia B, and Polyethylene.
  • Based on Distribution, market is studied across E-commerce, Hospital Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of cases of hemophilia
      • 5.1.1.2. Rising diagnostic and awareness related to Hemophilia
      • 5.1.1.3. Increasing demand for recombinant and plasma-derived factor VIII and factor IX
    • 5.1.2. Restraints
      • 5.1.2.1. Serious adverse effects associated with plasma-derived products
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased diagnosis rate and rise in the use of prophylactic treatment
      • 5.1.3.2. Emerging advances and innovations in hemophilia treatment
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of recombinant products and stringent government regulations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hemophilia Treatment Market, by Product Type

  • 6.1. Introduction
  • 6.2. Antifibrinolytic Agents
  • 6.3. Desmopressin
  • 6.4. Plasma Derived Coagulation Factor Concentrates
  • 6.5. Recombinant Coagulation Factor Concentrates

7. Hemophilia Treatment Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Hemophilia A
  • 7.3. Hemophilia B
  • 7.4. Polyethylene

8. Hemophilia Treatment Market, by Distribution

  • 8.1. Introduction
  • 8.2. E-commerce
  • 8.3. Hospital Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Hemophilia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hemophilia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hemophilia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aptevo Therapeutics
  • 2. Biogen Inc.
  • 3. Biotest AG
  • 4. Bioverativ Inc.
  • 5. CSL Behring
  • 6. F. Hoffmann-La Roche AG
  • 7. Ferring B.V.
  • 8. Genentech, Inc.
  • 9. Grifols SA
  • 10. Kedrion S.P.A
  • 11. LAKEMEDEL AB
  • 12. Novo Nordisk A/S
  • 13. Octapharma AG
  • 14. Pfizer Inc.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. HEMOPHILIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. HEMOPHILIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMOPHILIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMOPHILIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PLASMA DERIVED COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY POLYETHYLENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023